ReviewBMC oral health2026
Oral lichenoid lesions in association with immunotherapies: a report of two cases and a review of published work.
Review in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundA variety of drug-induced oral lichenoid lesions (OLLs) have been extensively reported in the literature, but the diagnosis and recognition of OLLs remain challenging for clinicians. To date, a wide range of drugs, including anti-inflammatory drugs, antihypertensives, antibiotics and others, have been suggested to cause OLLs with different presentations. To the best of our knowledge, immunotherapies are becoming increasingly preferred treatments for systemic diseases. At the same time, oral adverse events, including OLLs due to immunotherapies, are not widely appreciated. CASE PRESENTATION: We present two cases of OLLs in patients with ankylosing spondylitis and follicular lymphoma in whom different immunotherapies, including sulfasalazine and obinutuzumab, were used. The oral lesions presented reticular, atrophic, and ulcerated patterns. The patients' oral lesions improved after the administration of glucocorticoid therapy and the cessation of immunoregulatory treatment.
conclusionThis article describes two rare and representative cases related to OLLs induced by immunotherapies to update our knowledge of the drugs used by patients and improve the management, recognition and reporting of oral adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.